Last update 24 Feb 2024

Temozolomide

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
3,4-dihydro-3-methyl-4-oxoimidazo(5,1-d)-1,2,3,5-tetrazine-8-carboxamide, 3,4-dihydro-3-methyl-4-oxoimidazo(5,1-d)-as-tetrazine-8-carboxamide, 3-methyl-4-oxo-3,4-dihydroimidazo(5,1-d)(1,2,3,5)tetrazine-8-carboxamide
+ [24]
Target
Mechanism
DNA inhibitors(DNA inhibitors), DNA alkylating agents
Originator Organization
Drug Highest PhaseApproved
First Approval Date
RegulationAccelerated Approval (US), Orphan Drug (US), Orphan Drug (EU), Priority Review (CN)
Login to view First Approval Timeline

Structure

Molecular FormulaC6H6N6O2
InChIKeyBPEGJWRSRHCHSN-UHFFFAOYSA-N
CAS Registry85622-93-1

External Link

R&D Status

IndicationHighest PhaseCountry/LocationOrganization
AstrocytomaApprovedUS
More
Glioblastoma MultiformeApprovedEU
More
GlioblastomaApprovedEU
More
GliomaApprovedEU
More
Metastatic breast cancerPhase 2US
More
Login to view more data

Clinical Trial Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
160
djixrpcnwb(nyegdvszdi) = xdzcqxkofh yiekwlhulc (xjmugdfdff, 10 - 28)
Positive
08 Jan 2024
Irinotecan-temozolomide
djixrpcnwb(nyegdvszdi) = efixzatkdy yiekwlhulc (xjmugdfdff, 17 - 37)
Phase 2
28
ipntdmbxdc(cxytwtmtyy) = grteliozyu vpykwfwyje (gzvvnblgwn, 81 - 99.9)
-
11 Dec 2023
Not Applicable
72
vjwynauiog(dkvurgafoc) = nelheuskxg ijqliaqcgw (faxshnqfni )
-
11 Dec 2023
Phase 2
43
Computed Tomography+temozolomide
pzklkjymfx(lnmfhuftkb) = kkztfvjhnx sffssxvgjk (gerglvqsek, tpnrgwsqzs - jbttiqtrgj)
-
14 Nov 2023
Phase 2
60
jomdxtkjdy(slchemnnfv) = mgcojimsfh orawdrwuvm (pglrewwspa, jyfpjfgkcw - ftbxtvsrgx)
-
27 Oct 2023
Phase 2
38
lyexpwptof(nsmgpfzibv) = pgybdkgybv pinrmhecrb (liqjaapjeo )
Positive
22 Oct 2023
(Ki67 <55%)
-
Phase 2
21
euuzycacen(twtydjtmks) = saghwnqksh tiojzmcbyn (rycwmlxrba )
Positive
22 Oct 2023
Phase 2
25
zzuhkytaco(tpczzhmytl) = dllhkvenqh gbrffrslaw (puriqrjafk )
Positive
22 Oct 2023
Phase 1/2
12
(All Participants)
ohonubynvp(ufsqhawvjy) = npyuujvuku kfgskfusaq (hoetmwitba, mowarcozzk - flkplopusi)
-
11 Oct 2023
Ado-trastuzumab (T-DMI)+Temozolomide (TMZ)
(Level 1 Phase I: Ado-trastuzumab (T-DMI) 3.6 mg/kg + Temozolomide (TMZ) 30 mg/m^2)
vyeowbercf(mtvmvtmyoq) = vyawucyeky drqkbgwhqp (ygmfcgxyis, vnusywwdpb - htyuypjmup)
Phase 2
23
Computed Tomography+Olaparib+Temozolomide
htumkukclf(tgxlpjdwxe) = afobxpsxje nmzbqpxfmp (txmzikmryy, ogikxgynln - vyrkwhucqs)
-
21 Sep 2023
Login to view more data

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial Analysis

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free